CTLA4 and melanoma: As for the B16 melanoma model, AccuTOX® was mostly efficient when combined with anti-PD-1 (orange line) followed by both anti-CTLA-4 (red line) and anti-CD47 (yellow line—Fig. 2F) with a survival rate of 100% for the anti-PD-1 versus 80% for anti-CTLA-4 or anti-CD47 (Fig. 2G).